Your email has been successfully added to our mailing list.

×
0.0333333333333334 0.0333333333333334 0.0333333333333334 0.1 0.0833333333333334 0.1 0.0333333333333334 0.0331666666666667
Stock impact report

AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

AVEO Pharmaceuticals, Inc. (AVEO) 
Last aveo pharmaceuticals, inc. earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.aveooncology.com
Company Research Source: Business Wire
- Data Presented at the 2020 ASCO GI Cancers Symposium - CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The results were presented during a poster session at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium. A copy of the presentation, titled “Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer” (abstract 693), is available in the Publications & Presentations section of AVEO’s website.The study, which was based on preclinical findings demonstrating a synergistic effect of the combination in a preclinical Show less Read more
Impact Snapshot
Event Time:
AVEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AVEO alerts
Opt-in for
AVEO alerts

from News Quantified
Opt-in for
AVEO alerts

from News Quantified